Abstract:We analyzed patterns in recurrent major osteoporotic fracture (MOF) following a first major osteoporotic fracture in a large population-based cohort. Re-fracture risk remained elevated over 10 years, with only modest and inconsistent attenuation in risk over time. Introduction: Recurrent fracture risk remains elevated for up to 25 years, and is reportedly highest in the initial 2 years (imminent risk). Our aim was to characterize early time dependency in re-fracture rates up to 10 years after a first fracture in a population-based cohort. Methods: Using Province of Manitoba (Canada) healthcare databases, we performed a matched cohort study in 22,105 women (mean age 74.1 ± 10.6 years) and 7589 men (mean age 71.8 ± 11.2 years) after a first MOF (age ≥ 50 years) during 1989-2006 and matched fracture-free controls (3 for each case). Incident fractures were ascertained over the next 10 years. Fracture rate ratios (RRs, cases versus controls) stratified by sex and age were computed, and tested for linear trend using linear regression. Joinpoint regression was performed to determine non-linear change in fracture rates over time, with particular attention to the first 2-year post-fracture. Results: RRs for incident MOF and hip fracture exceeded unity for the primary analyses in all subgroups and follow-up intervals. There was a tendency of RRs to decline over time, but this was inconsistent. Absolute rates per 100,000 person-years for fracture cases were consistently greater than for controls in all subgroups and observation times. Among fracture cases, there was a tendency for rates to decline gradually in all subgroups except younger women, but these temporal trends appeared monotonic without an inflection at 2 years. Joinpoint regression analyses did not detect an inflection in risk between the first 2 years and subsequent years. No significant time dependency was seen for incident hip fracture. Conclusions: MOF and hip re-fracture risk was elevated in all age and sex subgroups over 10 years. There was inconsistent and only modest time dependency in early MOF risk, most evident in women after age 65 years. No strong transition in risk was seen between the first 2-year post-fracture and subsequent years.

Refracture and mortality risk in the elderly with osteoporotic fractures: the AGES-Reykjavik study

Risk of Subsequent Fractures and Mortality in Elderly Women and Men with Fragility Fractures with and without Osteoporotic Bone Density: The Dubbo Osteoporosis Epidemiology Study

Risk factors of refracture after a fragility fracture in elderly

Fracture Burden: What Two and a Half Decades of Dubbo Osteoporosis Epidemiology Study Data Reveal About Clinical Outcomes of Osteoporosis

Time dependency in early major osteoporotic and hip re-fractures in women and men aged 50 years and older: a population-based observational study

In community-dwelling women frailty is associated with imminent risk of osteoporotic fractures

Should patients with exceptional longevity be treated for osteoporosis after a hip fracture?

Male-female spatio-temporal differences of age-related bone changes show faster bone deterioration in older women at femoral regions associated with incident hip fracture

Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures

Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective

Prediction of Fragility Fractures and Mortality in a Cohort of Geriatric Patients

Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX

Vertebral Fractures in Ireland: A Sub-Analysis of the DXA HIP Project

Incident Fragility Fractures Have a Long-Term Negative Impact on Health-Related Quality of Life of Older People: The Canadian Multicentre Osteoporosis Study

Following hip fracture, hospital organisational factors associated with prescription of anti-osteoporosis medication on discharge, to address imminent refracture risk: a record-linkage study

Are osteoporotic fractures due to osteoporosis? Impacts of a frailty pandemic in an aging world

Recurrent Fragility Fractures: A Cross-sectional Analysis

Hip fracture, mortality risk, and cause of death over two decades

Anti-fracture treatment efficacy by age

Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk

Analysis of the clinical risk factors of re-fracture after osteoporotic fracture